Ionis Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Ionis Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Ionis Pharmaceuticals Inc Strategy Report
- Understand Ionis Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Ionis Pharmaceuticals Inc (Ionis), formerly ISIS Pharmaceuticals Inc, focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, pulmonary, cardiovascular diseases, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy and Waylivra for familial chylomicronemia syndrome. Ionis also has a pipeline of products in different phases of clinical trials. It develops products based on its proprietary antisense technology. The company partnered with other pharmaceutical companies to develop a range of products in different therapeutic areas. The company sells its products in North America and Europe. Ionis is headquartered in Carlsbad, California, the US.
Headquarters
United States of America
Address
2855 Gazelle Court, Carlsbad, California, 92010
Website
www.ionispharma.com
Telephone
1 760 9319200
No of Employees
927
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IONS (NASD)
Revenue (2022)
$787.6M
34.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-35.8%
(2022 vs 2021)
Market Cap*
$6.1B
Net Profit Margin (2022)
XYZ
-1.3%
(2022 vs 2021)
* As of and is in US$
Ionis Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Nusinersen - Spinal Muscular Atrophy | - |
| Inotersen - Polyneuropathy | Spinraza |
| Volanesorsen - Familial Chylomicronemia Syndrome | Tegsedi |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In August, the company signed a collaboration and license agreement with Novartis for the discovery, development, and commercialization of a novel medicine for patients with lipoprotein(a), or Lp(a)-driven cardiovascular disease. |
| 2023 | Contracts/Agreements | In July, the company entered into a multi-disease area collaboration with Scipher Medicine for advancing, developing and commercializing oligonucleotide therapies directed to targets discovered by Scipher’s Spectra platform. |
| 2023 | Contracts/Agreements | In July, the company expanded its partnership with AstraZeneca to include exclusive rights for AstraZeneca to commercialize eplontersen in Latin America. |
Competitor Comparison
| Key Parameters | Ionis Pharmaceuticals Inc | Alnylam Pharmaceuticals Inc | Intercept Pharmaceuticals Inc | Arrowhead Pharmaceuticals Inc | Enzo Biochem Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Carlsbad | Cambridge | Morristown | Pasadena | Farmingdale |
| State/Province | California | Massachusetts | New Jersey | California | New York |
| No. of Employees | 927 | 2,100 | 341 | 525 | 179 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Joseph Loscalzo, M.D., Ph.D. | Chairman | Executive Board | 2021 | 71 |
| Brett P. Monia, Ph.D. | Chief Executive Officer; Director | Executive Board | 2020 | 61 |
| Elizabeth L. Hougen | Executive Vice President - Finance; Chief Financial Officer | Senior Management | 2013 | 61 |
| Darren Gonzales | Senior Vice President; Chief Accounting Officer | Senior Management | - | - |
| Patrick R. O’Neil | Secretary; Chief Legal Officer; General Counsel | Senior Management | 2021 | 49 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward